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The sympathetic nervous system and the adrenergic receptors play an important role in regulation of blood pressure. This
study explored the associations between functional polymorphisms of the α2B-, β1-, and β2-adrenergic receptor genes and
obstructive sleep apnea (OSA) in hypertensive patients and hypertension in patients with OSA in a populationbased sample of
157 hypertensive patients and 181 healthy control subjects. Only the Arg389Gly polymorphism of the β1-adrenergic receptor
gene was associated with increased risk for mild OSA in hypertensive patients (Arg/Arg versus Gly/Arg/Gly/Gly, 2.1, 95% CI,
1.02–4.7). Hypertensive men carrying the Arg389Arg genotype had higher crude and age-adjusted AHI than carriers of the
Arg389Gly/Gly389Gly genotypes. When adjusted also for BMI this diﬀerence became borderline signiﬁcant. This diﬀerence was
not observed in women. The risk of hypertension in mild OSA was associated with increasing number of Arg-alleles (Arg/Arg OR
5.4, 95% CI 1.4–21.2).
1.Introduction
Obstructive sleep apnea (OSA) is a disorder characterized
by upper airway collapse and is common in middle-aged
adults [1]. OSA often leads to hypoxia and activation of
the sympathetic nervous system [2, 3] which might lead to
adverse metabolic reactions and high blood pressure [4, 5].
OSA has in humans been associated with hypertension [6, 7]
and cardiovascular complications [8, 9]. In an earlier study
of a population-based sample of hypertensive patients and
normotensive controls from primary care in Sweden, OSA
was found to be more prevalent in hypertensive patients,
speciﬁcally in male patients compared to controls, 83%
versus 64% (58% versus 49% in females) when OSA was
deﬁned as apnea/hypopnea index (AHI) ≥ 10 events per
hourand47%versus25%(26%versus24%infemales)when
OSA was deﬁned as AHI ≥ 30 events per hour [7].
The sympathetic nervous system plays an important role
in regulation of blood pressure and the adrenergic receptors
are important components of this system. The aim of this
study was to explore the associations between functional
polymorphisms of the α2B-, β1-, and β2-adrenergic receptor
genes and occurrence of OSA in hypertensive patients and
occurrence of hypertension in patients with OSA in a
population-based sample.
The α2A-adrenergic receptor and the α2B-adrenergic
receptor are expressed in the central nervous system. Blood
pressure is regulated by the opposing action of these2 International Journal of Hypertension
receptors upon agonist binding. The α2A-adrenergic receptor
has an inhibiting eﬀect on the sympathetic outﬂow while
the α2B-adrenergic receptor has an excitatory eﬀect [10].
The α2B-adrenergic receptor gene is located on chromosome
2 in a region where several genome scans, including one
from the population in the current study [11], have found
linkage to blood pressure variation and hypertension [12–
14]. In the third intracellular loop of the receptor, in an area
of importance in downregulation, there is a polymorphism
consisting of either an insertion (I) or a deletion (D) of three
amino acids at positions 301–303. Earlier studies have shown
that the deletion variant confers an increased activity in the
sympathetic nervous system [15] and that it is associated
with hypertension in the current and other populations
[16, 17].
The β1-adrenergic receptor is expressed in cardiac
myocytes [18] and upon agonist binding it confers excitatory
reactions in the myocyte leading to higher cardiac output
through increased cardiac inotropy and chronotropy.
The β1-adrenergic receptor gene on chromosome 10
harbors two polymorphisms with functional properties. The
Ser49Gly, locatedinthe extracellularportion ofthe receptor,
has been associated with variations in resting heart rate
in a dose dependent way [19]. The other polymorphism,
Arg389Gly, is located in the intracellular cytoplasmic tail
of the receptor near the seventh transmembrane region,
where the stimulatory G-protein probably binds. In vitro
studieshaveshownthattheArg389variantmediatesahigher
isoproterenol stimulated adenylate cyclase activity than the
Gly389 variant [20]. Homozygous carriers of Arg389 have
beenshowntohaveahigherriskforhypertensionandhigher
diastolic blood pressure levels and heart frequency than
carriers of the other genotypes in the current population
[21] and a minor inﬂuence on both systolic and diastolic
blood pressure in a larger population [22]. The homozygous
Arg389 carriers have also been shown to have a greater blood
pressure lowering response to atenolol [23]a n dm e t o p r o -
lol [24] compared with the homozygous Gly389 carriers
strengthening its functional importance in cardiovascular
regulation. Whether the polymorphism is associated with
higher risk for cardiovascular complications is not clear
[25, 26]. Recently, it has been shown that the Arg389Gly
polymorphismcanmodifythebeneﬁcialeﬀectofcontinuous
airway pressure [27].
The β2-adrenergic receptor is expressed in most arteries
in the body and in the heart and also in the respiratory
tract. Upon agonist binding it elicits dilation of the arteries
and bronchi. The β2-adrenergic receptor gene is located on
chromosome 5 in an area where already in 1996 genetic
variation was found to be associated with hypertension
[28]. Linkage to blood pressure levels has been found in
genome wide scans [29] and subsequent ﬁne mapping
has revealed association between hypertension and the β2-
adrenergic receptor gene variants [30] in the cytoplasmic
tail of the receptor. Two polymorphisms, the Arg16Gly and
Gln27Glu, have been found in vitro to confer diﬀerent
degree of downregulation of the receptor [31]. Studies on
humans have given conﬂicting results possibly because the
two polymorphisms have diﬀerent properties and are in
linkage disequilibrium with each other [32]. In the Ectim
and PEGASE studies there was no association between the
polymorphisms of the receptor and myocardial infarction
[33]. In studies of Scandinavian subjects, the Arg16 and
Gln27 variants were found to be associated with an increased
risk of hypertension [34] and with hypertension associated
with type 2 diabetes [35].
2.SubjectsandMethods
2.1. Study Population. The Skaraborg Hypertension and
Diabetes Project cohort have previously been described in
detail [36]. This sample comprises the majority of patients
with hypertension and/or type 2 diabetes (n = 1149)
in the local community of Skara investigated in 1992-
1993 and an age-stratiﬁed, random sample from 40 years
of age from Skara population (n = 1109) that was
investigated in 1993-1994 [37]. In 2000, a random sample
of hypertensive and normotensive men and women from
40 to 64 years at the baseline investigations was drawn
from the previous cohorts. The diagnosis of hypertension
was based upon at least three consecutive diastolic blood
pressure measurements ≥90mmHg diastolic blood pressure
(DBP) according to the current National Guidelines [38, 39]
or ongoing antihypertensive treatment at baseline. Most
hypertensive subjects in the present study (at least 85%)
were already diagnosed according to the criteria used before
1989 (≥160/95mmHg, WHO, 1989 [40]) and had ongoing
antihypertensive treatment. Normotension was deﬁned as
a systolic blood pressure (SPB) < 160mmHg and a DBP
< 90mmHg and no antihypertensive medication. Type 2
diabetes was diagnosed according to the current WHO rec-
ommendations [41] in 21 hypertensive patients. A full-night
polysomnography (PSG) at home was performed in 344
subjects,161 patients withhypertension, and181 individuals
without hypertension. The local ethics committee approved
the study and written informed consent was obtained from
all the participants.
2.2. Study Procedure. At baseline 1992–1994 all subjects
were surveyed for cardiovascular disease (CVD) risk factors
using a previously published protocol [42]. Sleep studies
were conducted during 2000–2002. A specially trained study
nurse performed the basic investigations. The blood pressure
was measured with Tricuﬀ [43] in the supine position
with a sphygmomanometer after 5 minutes of rest. A
standardised interview on medical history and medications
was performed and a questionnaire on sleep quality, daytime
sleepiness, and symptoms of depression was administered
[44]. Height was measured to the nearest centimetre and
weight to the nearest 0.1kg and body mass index (BMI) was
calculated. A full night PSG recording was performed in the
subjects’homeusingaportableEmbla-A10polysomngraphy
system (Flaga, Reykjavik, Iceland). Each recording included
three-channel electroencephalography (EEG, C4/A1,C 3/A2),
two-channel electrooculography, and one-channel submen-
tal electromyography (EMG). Limb movements were mon-
itored by tibial surface electrodes. Ventilatory monitoring
included oxygen saturation (SaO2) by an oximeter probe,International Journal of Hypertension 3
respiratory movements by chest and abdominal belts, nasal
and oral airﬂow by thermistor and nasal pressure by pressure
sensors. Two cotrained staﬀ members manually scored the
recordings according to a validated scoring manual [45]. A
successful PSG required a minimum of 4 hours sleeping time
including at least one REM-sleep period. The number of
apnea/hypopnea events per hour of sleep (AHI) was used
to dichotomise subjects into two groups, one with a cutoﬀ
level of 10 events per hour (mild OSA, OSA10, AHI ≥ 10
events per hour) and one with a cutoﬀ level of 30 events
per hour (severe OSA, OSA30, AHI ≥ 30 events per hour).
Separate statistical analyses were undertaken to compare the
two groups with the control subjects (those with AHI <10
and <30 events per hour, resp.).
2.3. Genotyping. High molecular weight DNA was extracted
from blood leukocytes according to standard techniques
[46] and used as template in all polymerase chain reactions
(PCRs). The genotyping procedures have been described
elsewhere [16, 35, 47]. The PCR conditions and digestion
conditions in the restriction fragment length polymorphism
(RFLP) reactions are shown in Table 1.
2.4. Statistical Methods. Hypertensive and normotensive
subjects were analysed separately. Continuous variables are
presented as means ± standard deviation (SD) and discrete
variables as frequencies (%). Diﬀerences between means
were tested by ANCOVA. Diﬀerences in proportions were
tested by χ2-test and by logistic regression. Confounding
from age and sex was accounted for by multivariate analyses
or by stratiﬁcation. Multiple logistic regressions were per-
formed with mild OSA (OSA10) and severe OSA (OSA30)
as the dependent variable and with age, sex, BMI and
the α2B-adrenergic receptor, β1-a n dβ2-adrenergic receptor
polymorphisms as independent variables. Associations were
expressed as odds ratio (OR) with 95 per cent conﬁdence
interval (95% CI). For the α2B-adrenergic receptor gene
the II genotype was used as reference in the comparison
with the ID and DD genotypes. For the β1-adrenergic
receptor gene the combination of Ser49Gly and Gly49Gly
was used as a reference and compared with the Ser49Ser
genotype. The combination of Gly389Gly and Arg389Gly
genotypes was used as reference and compared with the
Arg389Arg genotype. Finally, for the β2-adrenergic receptor
gene the Gly16Gly and Glu27Glu genotypes were used
as references compared with the Arg16Gly and Arg16Arg
and the Gln27Glu and Gln27Gln genotypes, respectively.
Analyses were carried out using SPSS Base system for
Macintosh 11.0 (Chicago, SPSS Inc.). All statistical tests were
two sided. P-values less than .05 were considered statistically
signiﬁcant.
3. Results
The clinical characteristics of the subjects are shown in
Table 2.Asexpectedhypertensivepatientshadhighersystolic
and diastolic blood pressure but were also older and had
higher BMI than normotensive subjects. AHI was higher in
hypertensive men but did not diﬀer between hypertensive
and normotensive women. The observed genotype frequen-
cies were all in Hardy Weinberg equilibrium.
3.1. The α2B-Adrenergic Receptor. T h eg e n o t y p ef r e q u e n c i e s
of the α2B-adrenergic receptor gene were 15% for DD
genotype, 51% for ID genotype, and 34% for the II
genotype. There was no statistical diﬀerence in genotype
or allele frequencies of the 301–303 I/D polymorphism in
hypertensive patients with or without OSA (Table 3)o ri n
normotensive controls (data not shown).
3.2. The β1-Adrenergic Receptor. The Arg389Arg genotype
of the β1-adrenergic receptor gene was more common in
male hypertensive patients with mild OSA than in those
without mild OSA (Table 3). There was a similar trend
in hypertensive females and in hypertensive males with
severe OSA. Among the 62 analyzed men there was no one
with OSA carrying the Gly389Gly genotype (Table 3). In
a recessive model comparing Arg389Arg to Arg389Gly and
Gly389Gly there was a signiﬁcant association with mild OSA
in hypertensive subjects, OR 2.3 (95% CI 1.10–4.87), P =
.027, crude and when adjusted for age and sex OR 2.3 (95%
CI 1.09–4.96), P = .029 and still signiﬁcant when adjusted
also for BMI OR 2.1 (95% CI 1.02–4.71), P = .045. In sex
speciﬁc analysis the patterns were very similar in men and
women; however, neither crude nor adjusted models turned
out signiﬁcant. In the full model we found OR 3.4 (95% CI
0.85–13.40), P = .085 in men, and 2.26 (95% CI 0.85–5.99),
P = .102 in women, respectively. Hypertensive men carrying
the Arg389Arg genotype had higher crude and age-adjusted
AHI than carriers of the Arg389Gly/Gly389Gly genotypes.
When adjusted also for BMI this diﬀerence became border-
line signiﬁcant. This diﬀerence was not observed in women
(Table 4). There was also a dose dependent increase in AHI
according to genotype being the lowest in Gly389Gly carriers
increasing in the Arg389Gly and the highest in Arg389Arg
carriers, signiﬁcant in all men (15.0 ± 13.7, 24.3 ± 18.5 and
32.3 ± 26.2 events per hour, P = .017). In the subgroups of
men with and without hypertension AHI showed a similar
increasing trend, 4.0 (one subject), 27.2 ± 20.1 and 39.5 ±
27.7 events per hour, P = .065 and 16.1 ± 13.9, 21.8 ± 16.9,
and 25.9 ± 23.4 events per hour, P = .33, respectively. In
womennosuchtrendwasobserv ed(28.8±27.5,22.9 ±25.3,
and 23.7 ± 23.1 events per hour P = .72).
In analysis including both patients with hypertension
and normotensive controls subjects the frequency of hyper-
tension versus normotension diﬀered signiﬁcantly between
the diﬀerent genotype carriers in subjects with mild OSA
(Table 5). When using the number of Arg389 alleles as an
approximately linear variable the age and BMI adjusted OR
for hypertension in patients with mild OSA were for one
Arg389 allele 4.8 (95% CI 1.2–19.3), P = .028 and for
two Arg389 alleles 5.4 (95% CI 1.4–21.2), P = .015. A test
for trend adjusted for age, sex, and BMI also showed an
increased OR for hypertension with increasing number of
Arg389 alleles, OR 1.6, 95% CI 1.003–2.5, P = .048.
3.3. The β2-Adrenergic Receptor. Neither of the investigated
polymorphisms(Arg16GlyorGln27Glu)wasassociatedwith4 International Journal of Hypertension
Table 1: PCR and digestion conditions for genotyping of the the α2B-, β1-, and the β2-adrenergic receptor gene polymorphisms.
PCR conditions RFLP Gel‡‡
Gene/polymorphism Forward (sense) primer sequence
N successfully
genotyped
Reverse (antisense) primer sequence Size (bp) Annealing
T (
◦C)
Extension
time (s)
Mg2+
mmol/L Cycles Enzyme Time
(h)
%
338 A2BAR
I/D 301–303 5 -AGGGTGTTTGTGGGGCATCT 112/103 72 30 1.5 33 —3
5 -CAAGCTGAGGCCGGAGACACT
337∗ B1AR
Ser49Gly 5 -CCGGGCTTCTGGGGTGTTCC 562 64 30 1.5 35 EcoO109I 3 2
5 -GGCGAGGTGATGGCGAGGTAGC
Arg389Gly 5 -CGCTCTGCTGGCTGCCCTTCTTCC 530 64 30 1.5 33 BcgI 3 2
5 -TGGGCTTCGAGTTCACCTGCTATC
338 B2AR
Arg16Gly 5 -CGCCTTCTTGCTGGCACGCAAT ∗∗ 203 60 30 1.5 30 BsrDl 2 4.5
5 -CCAGTGAAGTGATGAAGTAGTT
Gln27Glu 5 -CCGGACCACGACGTCACCCAG ∗∗∗ 169 60 30 1.5 30 BstNl 2 4.5
5 -CCAGTGAAGTGATGAAGTAGTT
A2BAR: α2B-adrenergic receptor gene; B1AR: β1-adrenergic receptor; B2AR: β2-adrenergic receptor; Ag: agarose; bp: base pair.
∗The genotyping failed in one individual.
∗∗The underlined nucleotide is a mismatch to create a BsrDl recognition site in case of the Gly16-allele.
∗∗∗The underlined nucleotide is a mismatch to create a BstNl recognition site in case of the Glu27-allele.
‡‡The PCR products were separated on a multipurpose agarose gel (Ag) with ethidium bromideand visualised with UV-light.
Table 2: Clinical characteristics in normotensive and hypertensive men and women.
Normotensive subjects Patients with hypertension
Variables Mean (SD) Mean (SD) P
Men (n) 96 74
Age (years) 60 (6.3) 62 (6.2) .008
Systolic blood pressure (mmHg) 131 (13.2) 148 (15.7) <.001
Diastolic blood pressure (mmHg) 77 (7.5) 84 (6.7) <.001
Heart rate (beats per minute) 68 (8.3) 68 (8.2) .653
AHI (events per hour) 23 (20.4) 34 (25.6) .005
Body mass index (kg/m2) 26.8 (3.0) 29.5 (4.6) <.001
Women (n) 85 83
Age (years) 60 (7.1) 64 (5.7) <.001
Systolic blood pressure (mmHg) 132 (14.8) 150 (16.8) <.001
Diastolic blood pressure (mmHg) 75 (7.5) 83 (8.0) <.001
Heart rate (beats per minute) 70 (8.7) 69 (9.0) .944
AHI (events per hour) 22 (26.0) 25 (22.2) .655
Body mass index (kg/m2) 28.1 (4.8) 30.3 (5.7) .006
Data are mean (SD). Diﬀerences in means were analysed by general linear models with adjustment for age. AHI: apnea/hypopnea index.
increased risk of OSA in hypertensive subjects or with
hypertension in patients with OSA (data not shown).
4. Discussion
We describe an association between the Arg389Arg genotype
of the β1-adrenergic receptor gene and OSA in hypertensive
patients. Furthermore, occurrence of hypertension increased
in subjects with mild OSA with increasing number of Arg389
alleles. The Arg389Arg genotype carriers had a borderline
signiﬁcantly higher AHI than the Arg389Gly/Gly389Gly
carriers when adjusted for age and BMI. While the current
study was designed to investigate the risk of OSA in patients
with hypertension, the results showing that the risk of
hypertension in subjects with mild OSA was associated with
the Arg389 allele are in accordance with what have been
previously published on association between hypertension
and the Arg389Gly polymorphism [21].
Theβ1-adrenergicreceptorisimportantintheadrenergic
activation of the heart by increasing both the inotropic andInternational Journal of Hypertension 5
Table 3: Genotype frequencies of adrenergic receptor genes: α2B-adrenergic I/D, the β1 Ser49Gly and Gly389Arg, and the β2 Gly16Arg and
Gln27Glu polymorphisms in hypertensive patients with and without mild (panel A) and severe (panel B) obstructive sleep apnoea (OSA).
A Patients with mild OSA Patients without mild OSA P
α2B-adrenergic receptor gene I/D polymorphism (n = 157)
Genotype II ID DD II ID DD
Men OSA10 (n = 74) 18 (28.6) 32 (50.8) 13 (20.6) 5 (41.7) 6 (50.0) 1 (8.3) .50
Women OSA10 (n = 83) 20 (35.7) 27 (48.2) 9 (16.1) 9 (34.6) 11 (42.3) 6 (23.1) .73
β1 adrenergic receptor gene Ser49Gly and Gly389Arg polymorphisms (n = 156)
Genotype (Ser49Gly) S/S S/G G/G S/S S/G G/G P
Men OSA10 (n = 74) 37 (59.7) 24 (38.7) 1 (1.6) 9 (75.0) 3 (25.0) 0 (0.0) .58
Women OSA10 (n = 82) 39 (69.6) 12 (21.4) 5 (8.9) 20 (76.9) 6 (23.1) 0 (0.0) .29
Genotype(Gly389Arg) G/G G/A A/A G/G G/A A/A P
Men OSA10 (n = 74) 0 (0.0) 23 (37.1) 39 (62.9) 1 (8.3) 6 (50.0) 5 (41.7) .042
Women OSA10 (n = 82) 3 (5.4) 18 (32.1) 35 (62.5) 3 (11.5) 12 (46.2) 11 (42.3) .20
β2 adrenergic receptor Gly16Arg and Gln27Glu (n = 157)
Genotype (Gly16Arg) A/A A/G G/G A/A A/G G/G P
Men OSA10 (n = 74) 8 (12.9) 35 (56.5) 19 (30.6) 1 (8.3) 5 (41.7) 6 (50.0) .43
Women OSA10 (n = 83) 8 (14.0) 22 (38.6) 27 (47.4) 4 (15.4) 13 (50.0) 9 (34.6) .54
Genotype (Gln27Glu) Gn/Gn Gn/Gu Gu/Gu Gn/Gn Gn/Gu Gu/Gu P
Men OSA10 (n = 74) 24 (38.7) 28 (45.2) 10 (16.1) 1 (8.3) 8 (66.7) 3 (25.9) .13
Women OSA10 (n = 83) 17 (29.8) 27 (47.4) 13 (22.8) 10 (38.5) 10 (38.5) 6 (23.1) .70
B Patients with severe OSA Patients without severe OSA
α2B-adrenergic receptor gene I/D polymorphism (n = 157)
Genotype II ID DD II ID P
Men OSA30 (n = 74) 12 (34.3) 15 (42.9) 8 (22.9) 11 (27.5) 23 (57.5) 6 (15.0) .43
Women OSA30 (n = 83) 8 (36.4) 12 (54.6) 2 (9.1) 21 (35.0) 26 (43.3) 13 (21.7) .40
β1 adrenergic receptor gene Ser49Gly and Gly389Arg polymorphisms (n = 156)
Genotype (Ser49Gly) S/S S/G G/G S/S S/G G/G P
Men OSA30 (n = 74) 24 (68.6) 11 (31.4) 0 (0.0) 22 (56.4) 16 (41.0) 1 (2.6) .41
Women OSA30 (n = 82) 15 (68.2) 5 (22.7) 2 (9.1) 44 (73.3) 13 (21.7) 3 (5.0) .78
Genotype (Gly389Arg) G/G G/A A/A G/G G/A A/A P
Men OSA30 (n = 74) 0 (0.0) 10 (28.6) 25 (71.4) 1 (2.6) 19 (48.7) 19 (48.7) .11
Women OSA30 (n = 82) 2 (9.1) 7 (31.8) 13 (59.1) 4 (6.7) 23 (38.3) 33 (55.0) .83
β2-adrenergic receptor Gly16Arg and Gln27Glu (n = 157)
Genotype (Gly16Arg) A/A A/G G/G A/A A/G G/G P
Men OSA30 (n = 74) 2 (5.7) 22 (62.9) 11 (31.4) 7 (18.0) 18 (46.2) 14 (35.9) .19
Women OSA30 (n = 83) 4 (18.2) 8 (36.4) 10 (45.5) 8 (13.1) 27 (44.3) 26 (42.6) .76
Genotype (Gln27Glu) Gn/Gn Gn/Gu Gu/Gu Gn/Gn Gn/Gu Gu/Gu P
Men OSA30 (n = 74) 11 (31.4) 19 (54.3) 5 (14.3) 14 (35.9) 17 (43.6) 8 (20.5) .62
Women OSA30 (n = 83) 6 (27.3) 10 (45.5) 6 (27.3) 21 (34.4) 27 (44.3) 13 (21.3) .77
OSA10: subjects dichotomised by AHI < or ≥10 events/ hour; OSA30: subjects dichotomised by AHI < or ≥30 events/hour. P-values are estimated with chi-
2 test. A: (Arg) arginine; D: deletion; I: insertion; G: (Gly) Glycine; Gn:(Gln) Glutamine; Gu: (Glu) glutamic acid; S:(Ser) serine; HT: hypertensive; OSA:
obstructive sleep apnoea.
chronotropic responses upon agonist binding. The Arg389
variant of the β1-adrenergic receptor has been found to
increase both the basal and the isoprotenerol-stimulated
adenylate cyclase activity compared with the Gly389 variant.
Experimental hypoxia in rats is a powerful activator of
the sympathetic nervous system leading to increased blood
pressure[48].Thisisconsistentwithourresultsthatavariant
of the β1-adrenergic receptor that confers an increased cyclic
AMP activity and has been shown to be associated with
hypertension also could be associated with increased risk of
O S Ai nh y p e r t e n s i v ep a t i e n t s .T h eg e n d e rd i ﬀerence found
in this study could be due to the lower impact of the genetic
variants of the sympathetic nervous system in development
of OSA in females compared with males; instead anatomic
factors in the throat might play a greater role in females
[49]. The analysis of AHI in diﬀerent β1-adrenergic receptor
genotype carriers showed a signiﬁcant diﬀerence only in
males. In fact we found no diﬀerence in AHI between6 International Journal of Hypertension
Table 4: Diﬀerences in AHI between male and female carriers of the Arg389Gly genotypes of the Beta-1 adrenergic gene.
Gly389Gly/Arg389Gly Arg389Arg
AHI (events per hour) Mean (SE) Mean (SE) P (adjusted)
Males n = 96 n = 74
Normotensive subjects
(crude) 20.5 (3.0) 25.9 (2.9) .20
(adjusted for age) 20.1 (3.1) 26.3 (2.9) .15
(adjusted for age, BMI) 20.5 (3.0) 25.9 (2.8) .20
Hypertensive patients
(crude) 26.5 (4.6) 39.5 (3.8) .03
(adjusted for age) 26.3 (4.6) 39.6 (3.8) .03
(adjusted for age, BMI) 27.4 (4.5) 38.6 (3.7) .06
Females n = 85 n = 82
Normotensive subjects
(crude) 23.5 (4.1) 21.3 (3.9) .70
(adjusted for age) 23.4 (3.9) 21.3 (3.8) .70
(adjusted for age, BMI) 22.8 (3.7) 21.9 (3.5) .85
Hypertensive patients
(crude) 24.4 (3.7) 26.0 (3.3) .76
(adjusted for age) 23.9 (3.6) 26.3 (3.1) .61
(adjusted for age, BMI) 24.3 (3.6) 26.1 (3.1) .71
AHI: apnoea-hypopnoea index (events per hour). Data are mean (SE) and stepwise adjusted for age and age and BMI. One male hypertensive had missing
BMI.
Table 5: Frequency of hypertension in patients with mild obstructive sleep apnea according to Beta-1 adrenergic receptor Arg389Gly
polymorphism.
Beta-1 adrenergic Genotype Hypertension Normotension P
All (n = 229) n = 118 n = 111
Gly389Gly% 2.5 9.9
Gly389Arg% 34.8 37.8
Arg389Arg% 62.7 52.3 .043
Males (n = 124) n = 62 n = 62
Gly389Gly% 0 9.7
Gly389Arg% 37.1 37.1
Arg389Arg% 62.9 53.2 .039
P-values are estimated with chi-2 test.
female hypertensive patients and controls. This suggests
that hypertension plays a less important role in OSA in
women than in men. One limitation of this study is the
small number of subjects especially after dichotomization
into hypertension and normotension. In this particular
polymorphism where the Gly389Gly genotype has a low
frequency the data should be interpreted with care.
The polymorphisms in the other adrenergic receptor
genes (the α2B-adrenergic receptor and the β2-adrenergic
receptor) were not associated with OSA in this study
population.
The α2B-adrenergic receptor gene I/D 301–303 polymor-
phism studied here is proposed to inﬂuence the agonist-
induceddesensitizationofthereceptor.Wefoundnoassocia-
tion between this polymorphism and OSA in hypertensive or
normotensiveindividuals.Oneexplanationmightbethatthe
α2B-adrenergic receptor acts on a level of sympathetic action
that is only indirectly involved in the adrenergic response of
the heart to hypoxia induced during OSA.
The lack of association between polymorphisms of the
β2-adrenergic receptor and OSA is in accordance with the
results from a cohort with high prevalence of hypertension
from Germany [50] although the risk of myocardial infarc-
tions was associated with the polymorphisms. Furthermore,
these polymorphisms have been shown to be associated with
hypertension only in the presence of type 2 diabetes in the
current population [35]. Compared to the β1-adrenergic
receptor the β2-adrenergic receptor has a similar but less
pronounced eﬀect in the heart. This diﬀerence in action
could explain why the β2-polymorphisms investigated here
do not seem to be of importance in development of OSA in
hypertensive patients.International Journal of Hypertension 7
In conclusion, the Arg389Gly polymorphism of the β1-
adrenergic receptor was associated with increased risk of
OSA in hypertensive men and with hypertension in subjects
with mild OSA. Also, in men, there was a dose dependent
increase in AHI being the lowest in Gly389Gly carriers and
the highest in Arg389Arg carriers. These ﬁndings highlight
the role of the sympathetic nervous system in OSA and
hypertension.
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